Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.
Kawachi H, Yamada T, Tamiya M, Negi Y, Kijima T, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Morimoto K, Iwasaku M, Tokuda S, Shimose T, Takayama K. Kawachi H, et al. Among authors: yamada t. Oncoimmunology. 2025 Dec;14(1):2442116. doi: 10.1080/2162402X.2024.2442116. Epub 2024 Dec 16. Oncoimmunology. 2025. PMID: 39681395 Free PMC article.
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
Yoshimura A, Yamada T, Okura N, Takeda T, Furutani W, Kubota Y, Shiotsu S, Hiranuma O, Nishioka N, Chihara Y, Tamiya N, Kaneko Y, Uchino J, Takayama K. Yoshimura A, et al. Among authors: yamada t. BMC Cancer. 2018 Dec 11;18(1):1241. doi: 10.1186/s12885-018-5153-4. BMC Cancer. 2018. PMID: 30537950 Free PMC article.
Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients.
Katayama Y, Yamada T, Chihara Y, Tanaka S, Tanimura K, Okura N, Hirose K, Uda S, Shiotsu S, Hirai S, Hiranuma O, Harada T, Shimamoto T, Iwasaku M, Kaneko Y, Uchino J, Takeda T, Takayama K. Katayama Y, et al. Among authors: yamada t. Sci Rep. 2020 Oct 15;10(1):17495. doi: 10.1038/s41598-020-74573-0. Sci Rep. 2020. PMID: 33060826 Free PMC article.
Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients.
Morimoto K, Yamada T, Nakamura R, Katayama Y, Tanaka S, Takumi C, Hiraoka N, Ogura Y, Takeda T, Onoi K, Chihara Y, Taniguchi R, Yamada T, Matsui Y, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Morimoto K, et al. Among authors: yamada t. Med Oncol. 2020 Nov 11;37(12):111. doi: 10.1007/s12032-020-01440-3. Med Oncol. 2020. PMID: 33175248
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study.
Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Morimoto K, et al. Among authors: yamada t. Oncoimmunology. 2021 Jul 8;10(1):1950411. doi: 10.1080/2162402X.2021.1950411. eCollection 2021. Oncoimmunology. 2021. PMID: 34290909 Free PMC article.
Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer.
Morimoto K, Yamada T, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Morimoto K, et al. Among authors: yamada t. Lung Cancer. 2021 Nov;161:26-33. doi: 10.1016/j.lungcan.2021.08.015. Epub 2021 Aug 31. Lung Cancer. 2021. PMID: 34500218
Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study.
Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Morimoto K, et al. Among authors: yamada t. J Cancer Res Clin Oncol. 2022 Sep;148(9):2437-2446. doi: 10.1007/s00432-021-03782-5. Epub 2021 Sep 12. J Cancer Res Clin Oncol. 2022. PMID: 34510271
Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
Ishida M, Morimoto K, Yamada T, Shiotsu S, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Tokuda S, Takeda T, Takayama K. Ishida M, et al. Among authors: yamada t. Thorac Cancer. 2022 Jan;13(2):173-181. doi: 10.1111/1759-7714.14236. Epub 2021 Nov 17. Thorac Cancer. 2022. PMID: 34791812 Free PMC article.
12,271 results
You have reached the last available page of results. Please see the User Guide for more information.